Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almond Therapy Extension in Treatment Resistant Depression
NCT05438758Phase 2Withdrawn
- Sponsor
- Zylorion
- Start
- Jan 2023
- Primary completion
- Feb 2024
01
Overview
Phase 2, single-blind trial in major depressive disorder (MDD) (2 arms), sponsored by Zylorion. Primary endpoint: Montgomery Asberg Depression Rating Scale at Day 89. Planned start Jan 2023; status: withdrawn.
02
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05438758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438758.